Themis Medicare Ltd. (BSE: 530199) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹981 Cr, it ranks #1,609 by market cap among the 6,137 Indian listed companies on FinBizNet, and #49 of 86 in Medicinal Chemicals and Botanical Products. At ₹90.74 (as of 25 Oct 2026), the share price is 35.5% below its 52-week high of ₹140.60 and 39.7% above its 52-week low of ₹64.95. The share price is down 27.9% over one year and down 17.4% over three months.
| Current Price | ₹90.74 |
|---|---|
| Market Cap | ₹981 Cr |
| BSE Code | 530199 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 835 |
| Return on Equity | 0.29% |
| Return on Assets | -1.05% |
| 52-Week Range | ₹64.95 – ₹140.60 |
| 1-Year Price Change | -27.9% |
| 3-Month Price Change | -17.4% |
| Beta (1Y) | 0.44 |
| Dividend Yield | 0.50% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.themismedicare.com |
| Revenue | ₹87 Cr |
|---|---|
| Net Profit | ₹22 Cr |
| Net Margin | 25.3% |
| EPS (Basic) | ₹2.67 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopr
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, such as anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Themis Medicare Ltd. | ₹981 Cr | 835 | 0.29% | ₹87 Cr | -27.9% |
Listed by market capitalisation. Ratios are shown for context only.
Themis Medicare Ltd. is trading at ₹90.74, with a market capitalisation of ₹981 Cr.
Themis Medicare Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Themis Medicare Ltd. has a P/E of 835 and a return on equity of 0.29%.
Themis Medicare Ltd. is listed on the BSE under the scrip code 530199.
Themis Medicare Ltd.'s share price is down 27.9% over one year and down 17.4% over three months. Its 52-week range is ₹64.95 to ₹140.60.
In Q1 FY27, Themis Medicare Ltd. reported revenue of ₹87 Cr and net profit of ₹22 Cr, with basic EPS of ₹2.67 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.